CME/CE INFORMATION
Oncology Congress
Saturday, September 24, 2022 | Live CME/CE Conference
Broadcast starts at 8:00 AM CT
Integrating the Latest Evidence on Immune Checkpoint Inhibitors
Into the Management of Advanced Non-Small Cell Lung Cancer
Jointly provided by Postgraduate Institute for Medicine and RME Collaborative:
TARGET AUDIENCE
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
LEARNING OBJECTIVES
- Apply biomarker testing results to guide treatment decisions for non-small cell lung cancer (NSCLC)
- Differentiate treatment options for advanced NSCLC based on clinical safety and efficacy data
- Integrate clinical evidence and current guideline recommendations on immunotherapies into treatment plans for patients with advanced NSCLC
- Implement interprofessional strategies for reducing disparities in care access and treatment for NSCLC in rural and underserved settings
FACULTY
Mark G. Kris, MD
Professor of Medicine
Weill Cornell Medical College
Attending Physician, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Sucharu (Chris) Prakash, MD
Oncologist & Regional Medical Director
Texas Oncology - Paris
Paris, TX
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine and RME Collaborative adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies (commercial interests). All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Faculty
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Mark G. Kris, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from AstraZeneca Pharmaceuticals and Pfizer, Inc.; consultant/advisory board member for AstraZeneca Pharmaceuticals, BerGenBio, Daiichi Sankyo, Janssen Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Sanofi; and financial support for editorial services from Genentech, Inc.
Sucharu (Chris) Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.
Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.
ACKOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AbbVie, Inc.; Astellas; AstraZeneca Pharmaceuticals; Bayer HealthCare Pharmaceuticals, Inc.; Eisai, Inc.; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; and Seagen.
This session is supported by independent medical education grants from Eisai, Inc.; Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co., Inc.; and Regeneron Pharmaceuticals, Inc. and Sanofi.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Evolving Treatment Paradigms in HR-Positive, HER2-Negative Breast Cancer:
Integrating the Latest Evidence Into Clinical Practice
Jointly provided by Postgraduate Institute for Medicine and RME Collaborative:
TARGET AUDIENCE
This
activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
LEARNING OBJECTIVES
- Select appropriate adjuvant therapy or sequence of therapies for patients with HR-positive, HER2-negative early breast cancer
- Apply evidence-based strategies to guide personalized treatment planning for patients with metastatic HR-positive, HER2-negative breast cancer
- Integrate shared decision-making into the management of HR-positive, HER2-negative breast cancer to ensure patient goals and preferences are factored into treatment selection
- Discuss interprofessional strategies for improving breast cancer care and management in rural and underserved settings
FACULTY
Harold J. Burstein, MD, PhD
Professor of Medicine
Harvard Medical School
Medical Oncologist
Dana-Farber Cancer Institute
Boston, MA
Sucharu (Chris) Prakash, MD
Oncologist & Regional Medical Director
Texas Oncology - Paris
Paris, TX
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing
Education activity is 1.0 contact hour. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine and RME Collaborative
adhere to the ACCME’s Standards for Integrity and Independence in
Accredited Continuing Education. Postgraduate Institute for Medicine
requires faculty, planners, and others in control of educational content
to disclose all their financial relationships with ineligible companies
(commercial interests). All identified conflicts of interest (COI) are
thoroughly vetted and mitigated according to Postgraduate Institute for
Medicine policy. Postgraduate Institute for Medicine is committed to
providing its learners with high quality accredited continuing education
activities and related materials that promote improvements or quality
in healthcare and not a specific proprietary business interest of an
ineligible company.
Faculty
The
faculty reported the following relevant financial relationships with
ineligible entities related to the educational content of this CE
activity:
Harold J. Burstein, MD, PhD, has no relevant financial relationships to disclose.
Sucharu (Chris) Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.
Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.
ACKOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AbbVie, Inc.; Astellas; AstraZeneca Pharmaceuticals; Bayer HealthCare Pharmaceuticals, Inc.; Eisai, Inc.; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; and Seagen.
This session is supported by an independent medical education grant from AstraZeneca Pharmaceuticals.
DISCLOSURE OF UNLABELED USE
This
educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside
of the labeled indications. The opinions expressed in the educational
activity are those of the faculty and do not necessarily represent the
views of the planners. Please refer to the official prescribing
information for each product for discussion of approved indications,
contraindications, and warnings.
DISCLAIMER
Participants
have an implied responsibility to use the newly acquired information to
enhance patient outcomes and their own professional development. The
information presented in this activity is not meant to serve as a
guideline for patient management. Any procedures, medications, or other
courses of diagnosis or treatment discussed
or suggested in this activity should not be used by clinicians without
evaluation of their patient’s conditions and possible contraindications
and/or dangers in use, review of any applicable manufacturer’s product
information, and comparison with recommendations of other authorities.
Management of Urothelial Carcinoma: Strategies for Addressing
Health Disparities and Promoting Equitable Care
Jointly provided by Postgraduate Institute for Medicine and RME Collaborative:
TARGET AUDIENCE
This
activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
LEARNING OBJECTIVES
- Evaluate ways to improve multidisciplinary, coordinated care and communication for patients with urothelial carcinoma from rural and underserved settings
- Integrate current clinical evidence and guideline recommendations into treatment plans with new and emerging targeted therapies for patients with advanced/metastatic urothelial carcinoma
- Apply best practice strategies to monitor and manage adverse events associated with advanced/metastatic urothelial carcinoma therapy
FACULTY
Matthew D. Galsky, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director, Genitourinary Medical Oncology
Mount Sinai Hospital
New York, NY
Sucharu (Chris) Prakash, MD
Oncologist & Regional Medical Director
Texas Oncology - Paris
Paris, TX
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing
Education activity is 1.0 contact hour. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine and RME Collaborative
adhere to the ACCME’s Standards for Integrity and Independence in
Accredited Continuing Education. Postgraduate Institute for Medicine
requires faculty, planners, and others in control of educational content
to disclose all their financial relationships with ineligible companies
(commercial interests). All identified conflicts of interest (COI) are
thoroughly vetted and mitigated according to Postgraduate Institute for
Medicine policy. Postgraduate Institute for Medicine is committed to
providing its learners with high quality accredited continuing education
activities and related materials that promote improvements or quality
in healthcare and not a specific proprietary business interest of an
ineligible company.
Faculty
The
faculty reported the following relevant financial relationships with
ineligible entities related to the educational content of this CE
activity:
Matthew D. Galsky, MD, has disclosed the following relevant financial relationships: research/grant support from AstraZeneca Pharmaceuticals, Bristol Myers Squibb, Dendreon, Genentech, Inc., Merck & Co., Inc., and Novartis Pharmaceuticals Corporation; consultant/advisory board member for Alligator Bioscience, AstraZeneca Pharmaceuticals, Bristol Myers Squibb, EMD Serono, Genentech, Inc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Numab Therapeutics, Pfizer, Inc., Rappta Therapeutics, and Seagen.
Sucharu (Chris) Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.
Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.
ACKOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AbbVie, Inc.; Astellas; AstraZeneca Pharmaceuticals; Bayer HealthCare Pharmaceuticals, Inc.; Eisai, Inc.; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; and Seagen.
This session is supported by independent medical education grants from Astellas and Seagen; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
DISCLOSURE OF UNLABELED USE
This
educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside
of the labeled indications. The opinions expressed in the educational
activity are those of the faculty and do not necessarily represent the
views of the planners. Please refer to the official prescribing
information for each product for discussion of approved indications,
contraindications, and warnings.
DISCLAIMER
Participants
have an implied responsibility to use the newly acquired information to
enhance patient outcomes and their own professional development. The
information presented in this activity is not meant to serve as a
guideline for patient management. Any procedures, medications, or other
courses of diagnosis or treatment discussed
or suggested in this activity should not be used by clinicians without
evaluation of their patient’s conditions and possible contraindications
and/or dangers in use, review of any applicable manufacturer’s product
information, and comparison with recommendations of other authorities.
Mitigating Disparities in Prostate Cancer Care:
Strategies to Promote Equitable Care Across the Continuum
Jointly provided by Postgraduate Institute for Medicine and RME Collaborative:
TARGET AUDIENCE
This
activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
LEARNING OBJECTIVES
- Evaluate real-world strategies for overcoming disparities in prostate cancer treatment practices and patient outcomes
- Incorporate evidence-based risk stratification strategies to guide personalized treatment planning for patients with prostate cancer
- Assess the efficacy, safety, and appropriate sequencing of novel treatment options for advanced prostate cancer
- Assess multidisciplinary strategies for overcoming barriers to prostate cancer treatment and follow-up care in rural and underserved settings
FACULTY
Matthew R. Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine, Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, MA
Sucharu (Chris) Prakash, MD
Oncologist & Regional Medical Director
Texas Oncology - Paris
Paris, TX
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing
Education activity is 1.0 contact hour. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine and RME Collaborative
adhere to the ACCME’s Standards for Integrity and Independence in
Accredited Continuing Education. Postgraduate Institute for Medicine
requires faculty, planners, and others in control of educational content
to disclose all their financial relationships with ineligible companies
(commercial interests). All identified conflicts of interest (COI) are
thoroughly vetted and mitigated according to Postgraduate Institute for
Medicine policy. Postgraduate Institute for Medicine is committed to
providing its learners with high quality accredited continuing education
activities and related materials that promote improvements or quality
in healthcare and not a specific proprietary business interest of an
ineligible company.
Faculty
The
faculty reported the following relevant financial relationships with
ineligible entities related to the educational content of this CE
activity:
Matthew R. Smith MD, PhD, has disclosed the following relevant financial relationships: consultant/advisory board member for Astellas Pharma, Inc., Bayer, Janssen Pharmaceuticals, Eli Lilly and Company, and Pfizer, Inc.
Sucharu (Chris) Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.
Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AbbVie, Inc.; Astellas; AstraZeneca Pharmaceuticals; Bayer HealthCare Pharmaceuticals, Inc.; Eisai, Inc.; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; and Seagen.
This session is supported by independent medical education grants from Astellas and Pfizer, Inc.; AstraZeneca Pharmaceuticals; Bayer Healthcare Pharmaceuticals, Inc; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
DISCLOSURE OF UNLABELED USE
This
educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside
of the labeled indications. The opinions expressed in the educational
activity are those of the faculty and do not necessarily represent the
views of the planners. Please refer to the official prescribing
information for each product for discussion of approved indications,
contraindications, and warnings.
DISCLAIMER
Participants
have an implied responsibility to use the newly acquired information to
enhance patient outcomes and their own professional development. The
information presented in this activity is not meant to serve as a
guideline for patient management. Any procedures, medications, or other
courses of diagnosis or treatment discussed
or suggested in this activity should not be used by clinicians without
evaluation of their patient’s conditions and possible contraindications
and/or dangers in use, review of any applicable manufacturer’s product
information, and comparison with recommendations of other authorities.
Overcoming Barriers to Equitable Care in Hepatocellular Carcinoma:
Integrating New Evidence Into Clinical Practice
Jointly provided by Postgraduate Institute for Medicine and RME Collaborative:
TARGET AUDIENCE
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
LEARNING OBJECTIVES
- Apply clinical evidence on the efficacy and safety of systemic therapies for unresectable hepatocellular carcinoma (HCC) into clinical practice
- Develop personalized treatment plans that consider individual patient and disease characteristics as well as clinical profiles of therapeutic options for unresectable HCC
- Implement evidence-based strategies for reducing disparities in HCC care access and treatment in rural and underserved settings
FACULTY
Ghassan K. Abou-Alfa, MD, MBA
Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY
Sucharu (Chris) Prakash, MD
Oncologist & Regional Medical Director
Texas Oncology - Paris
Paris, TX
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine and RME Collaborative adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies (commercial interests). All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Faculty
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Ghassan K. Abou-Alfa, MD, MBA, has disclosed the following relevant financial relationships: research/grant support from Arcus Biosciences, AstraZeneca Pharmaceuticals, BioNTech, BMS, Celgene Corporation, Flatiron Health, Genentech, Inc./Roche, Genoscience Pharma, Incyte Corporation, Polaris Pharmaceuticals, Inc., Puma Biotechnology, Inc., QED Therapeutics, Silenseed, and Yiviva; consultant for Adicet Bio, Inc., Alnylam Pharmaceuticals, AstraZeneca Pharmaceuticals, Autem Therapeutics, BeiGene, Berry Genomics, Boehringer Ingelheim, Celgene Corporation, Cend Therapeutics, CytomX Therapeutics, Eisai, Inc., Eli Lilly and Company, Exelixis, Inc., Flatiron Health, Genentech, Inc./Roche, Genoscience Pharma, Helio Genomics, Helsinn Group, Incyte Corporation, Ipsen, Merck & Co., Inc., Nerviano Medical Sciences, NewBridge Pharmaceuticals, Novartis Pharmaceuticals Corporation, QED Therapeutics, RedHill Biopharma, Rafael Pharmaceuticals, Inc. (now Cornerstone Pharmaceuticals, Inc.), Servier Pharmaceuticals, Silenseed, Sobi, Vector Pharma, and Yiviva.
Sucharu (Chris) Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.
Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AbbVie, Inc.; Astellas; AstraZeneca Pharmaceuticals; Bayer HealthCare Pharmaceuticals, Inc.; Eisai, Inc.; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; and Seagen.
This session is supported by independent medical education grants from AstraZeneca Pharmaceuticals; Eisai, Inc.; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Updates in the Diagnosis and Management of Chronic Lymphocytic Leukemia:
Strategies for Addressing Disparities in Patient Care and Outcomes
Jointly provided by Postgraduate Institute for Medicine and RME Collaborative:
TARGET AUDIENCE
This
activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
LEARNING OBJECTIVES
- Integrate advances in chronic lymphocytic leukemia (CLL) testing to help diagnose, predict prognosis, and select personalized treatment for patients from rural and underserved communities
- Apply current guideline recommendations and clinical trial data to personalize treatment of CLL in both the frontline and relapsed/refractory settings for patients from rural and underserved communities
- Develop approaches to address CLL treatment adherence and adverse event monitoring and management, considering the unique challenges for rural and underserved settings
FACULTY
Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research, Division of Lymphoma
Attending Physician, Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, MA
Sucharu (Chris) Prakash, MD
Oncologist & Regional Medical Director
Texas Oncology - Paris
Paris, TX
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing
Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine and RME Collaborative
adhere to the ACCME’s Standards for Integrity and Independence in
Accredited Continuing Education. Postgraduate Institute for Medicine
requires faculty, planners, and others in control of educational content
to disclose all their financial relationships with ineligible companies
(commercial interests). All identified conflicts of interest (COI) are
thoroughly vetted and mitigated according to Postgraduate Institute for
Medicine policy. Postgraduate Institute for Medicine is committed to
providing its learners with high quality accredited continuing education
activities and related materials that promote improvements or quality
in healthcare and not a specific proprietary business interest of an
ineligible company.
Faculty
The
faculty reported the following relevant financial relationships with
ineligible entities related to the educational content of this CE
activity:
Matthew S. Davids, MD, MMSc, has disclosed the following relevant financial relationships: grant/research support from AbbVie, Inc., Ascentage Pharma, AstraZeneca Pharmaceuticals, Genentech, Inc., Novartis Pharmaceuticals Corporation, TG Therapeutics, Inc., and Verastem Oncology; consultant/advisory board member for AbbVie, Inc., Adaptive Biotechnologies, AstraZeneca Pharmaceuticals, BeiGene, Bristol Myers Squibb, Eli Lilly and Company, Genentech, Inc., Janssen Pharmaceuticals, Merck & Co., Inc., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company, TG Therapeutics, Inc., and Verastem Oncology.
Sucharu (Chris) Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.
Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AbbVie, Inc.; Astellas; AstraZeneca Pharmaceuticals; Bayer HealthCare Pharmaceuticals, Inc.; Eisai, Inc.; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; and Seagen.
This session is supported by an independent medical education grant from AbbVie, Inc.
DISCLOSURE OF UNLABELED USE
This
educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside
of the labeled indications. The opinions expressed in the educational
activity are those of the faculty and do not necessarily represent the
views of the planners. Please refer to the official prescribing
information for each product for discussion of approved indications,
contraindications, and warnings.
DISCLAIMER
Participants
have an implied responsibility to use the newly acquired information to
enhance patient outcomes and their own professional development. The
information presented in this activity is not meant to serve as a
guideline for patient management. Any procedures, medications, or other
courses of diagnosis or treatment discussed
or suggested in this activity should not be used by clinicians without
evaluation of their patient’s conditions and possible contraindications
and/or dangers in use, review of any applicable manufacturer’s product
information, and comparison with recommendations of other authorities.
MEDIA
Internet activity
COMPUTER SYSTEM REQUIREMENTS
- System checker: Must meet all requirements of Digitell Live Events Platform
- Operating system: Windows or Macintosh
- Supported browsers: HTML5-capable browser – Internet Explorer, Google Chrome, Mozilla Firefox, Safari, Microsoft Edge, Opera
- Hardware: computer, smartphone, or tablet
- Broadband Internet connection: high-speed connection preferable
FEE INFORMATION
There is no fee for this educational activity.
CONTACT US
General Questions
For general information or questions about this activity, please contact RME Collaborative at 800-913-9370 or cme@cmeruralhealth.com.
Accreditation Support
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine at inquiries@pimed.com.
COPYRIGHT
©RME Collaborative, a division of Talem Health, LLC 2022. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.